AI imaging software has moved from research demonstration to clinical deployment at scale. FDA-cleared AI algorithms for chest X-ray abnormality detection, CT pulmonary embolism diagnosis, mammography cancer detection, brain MRI stroke assessment, and automated organ segmentation are generating measurable clinical and workflow improvements. The commercial AI imaging software market is bifurcating between OEM-embedded AI and independent third-party AI marketplaces.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• FDA-Cleared AI Algorithm Landscape
• OEM AI Platform Comparison
• Third-Party AI Marketplace — Nuance, Aidoc, Viz.ai
• AI in Radiology Workflow
• Return on Investment Evidence
• Regulatory Pathway for AI Software
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Technology Landscape Overview
3. FDA-Cleared AI Algorithm Landscape
4. OEM AI Platform Comparison
5. Third-Party AI Marketplace — Nuance, Aidoc, Viz.ai
6. AI in Radiology Workflow
7. Return on Investment Evidence
8. Regulatory Pathway for AI Software
9. Competitive Landscape
10. Competitive Landscape
11. Strategic Conclusions and Recommendations
12. Appendix
List of Tables
Table 1. Technology Overview and Key Data 2025
Table 2. FDA-Cleared AI Algorithm Landscape
Table 3. OEM AI Platform Comparison
Table 4. Third-Party AI Marketplace
Table 5. AI in Radiology Workflow
Table 6. Return on Investment Evidence
Table 7. Regulatory Pathway for AI Software
Table 8. Competitive Landscape
Table 9. Leading Companies — Technology Investment and Strategy 2025
Table 10. M&A and Partnership Activity 2023-2025
Table 11. Key Risks and Mitigation Strategies
Companies Profiled
Aidoc
Change Healthcare
GE HealthCare
Intelerad
Nanox
Nuance
Philips
Siemens Healthineers
